REGistry of Long-term AnTithrombotic TherApy-2 (REGATTA-2)
Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Atrial Fibrillation
Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
A observational or N/A phase clinical study on Atrial Fibrillation, this trial is actively recruiting participants. The trial is conducted by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation and has accumulated 9 data snapshots since 2015. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Study Description(click to expand)The register is a Russian prospective single-center observational study of patients who have indications for long-term antithrombotic therapy in connection with atrial fibrillation
The register is a Russian prospective single-center observational study of patients who have indications for long-term antithrombotic therapy in connection with atrial fibrillation
Status Flow
Change History
9 versions recorded-
May 4, 2026 — Present [daily]
Recruiting
-
Sep 2025 — May 2026 [monthly]
Recruiting
-
Apr 2025 — Sep 2025 [monthly]
Recruiting
-
Sep 2024 — Apr 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
▶ Show 4 earlier versions
-
Dec 2021 — Jul 2024 [monthly]
Recruiting
-
Jan 2021 — Dec 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
May 2020 — Nov 2020 [monthly]
Recruiting
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with atrial fibrillation
Contact Information
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
For direct contact, visit the study record on ClinicalTrials.gov .